Let me walk through three areas of focus that we have for multipolar world in 2026
The benefits include once-daily dosing, as opposed to two to four times daily as required with sulfasalazine
We believe our miniature, ultra long-acting implants, designed to improve medication adherence, have the potential to improve efficacy and minimize tolerability issues.
- Upon thawing, the protein refolds incorrectly or aggregates into non-functional clumps
Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade
Other noteworthy phase 3 trial readouts in 2025 include: Novo Nordisks evoke/evoke+ , investigating oral semaglutide in patients with early Alzheimers disease, potentially expanding the utility of GLP-1s beyond cardiometabolic indications